Growing research finds weight-loss drugs could help treat addiction

By

min read

Emerging research suggests that medications originally developed for weight loss, such as Ozempic, might offer unexpected hope for those battling addiction. A new study published in JAMA Psychiatry adds to growing evidence that GLP-1 agonists—a class of drugs designed to regulate hunger and appetite—could also reduce the risks associated with substance use disorders.

GLP-1 agonists, like semaglutides (Ozempic, Wegovy) and liraglutides, mimic a hormone that helps control appetite. But their benefits appear to go beyond weight management.

In this study, researchers analyzed data from more than 227,000 people diagnosed with alcohol use disorder between 2006 and 2021. They found that those taking GLP-1 agonists were significantly less likely to be hospitalized for alcohol withdrawal or overdose. Specifically, semaglutides were associated with a 36% lower risk, and liraglutides with a 28% lower risk.

The impact wasn’t limited to alcohol. Those taking semaglutides had a 32% lower risk of hospitalization due to any substance use disorder, while liraglutides reduced the risk by 22%.

Earlier this year, as Emily’s Hope previously reported, a large-scale study of more than 503,000 people with opioid use disorder revealed similar findings. Those prescribed GLP-1 RA or GIP medications, including Ozempic and Mounjaro, experienced a 40% lower risk of opioid overdose compared to those without such prescriptions.

Recent Headlines

  • Minot, ND Police issue public alert after string of overdoses

    April 21, 2025
    Casey Wonnenberg-King Avatar
  • 17 hospitalized after exposure to unknown substance at federal prison in Illinois

    April 21, 2025
    Angela Kennecke Avatar
  • Federal drug sweep nets 16 arrests in Rapid City and Pine Ridge Reservation

    April 16, 2025
    Angela Kennecke Avatar